Synthesis and antibacterial evaluation of 13-substituted cycloberberine derivatives as a novel class of anti-MRSA agents

被引:29
作者
Fan, Tian-Yun
Wang, Yan-Xiang
Tang, Sheng
Hu, Xin-Xin
Zen, Qing-Xuan
Pang, Jing
Yang, Yuan-Shuai
You, Xue-Fu [1 ]
Song, Dan-Qing [1 ]
机构
[1] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing Key Lab Antimicrobial Agents, Beijing 100050, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Cycloberberine; Antibacterial; Structure-activity relationship; MRSA; Synthesis; RESISTANT STAPHYLOCOCCUS-AUREUS; BIOLOGICAL EVALUATION; BERBERINE ANALOGS; INFECTIONS; DAPTOMYCIN; VANCOMYCIN; DISCOVERY;
D O I
10.1016/j.ejmech.2018.08.050
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of new 13-substituted cycloberberine (CBBR) derivatives were prepared and evaluated for their antibacterial activities against Gram-positive bacteria taking CBBR as the lead. Structure-activity relationship revealed that the introduction of a suitable electron-donating group at the 13-position in CBBR might be beneficial for the antibacterial potency. Among them, compounds 5b and 5w exhibited high potency against methicillin-sensitive (MSSA) and resistant strains of S. aureus (MRSA) with MIC values of 1-4 mu g/mL. Both of them also displayed high stabilities in blood, and good in vivo safety profiles with LD50 values of 65.6 and 41.2 mg kg(-1) in intravenous route respectively. Molecular docking analysis indicated that compound 5b might target FtsZ protein that could inhibit cell division, with the advantage of activity against multidrug resistant S. aureus. Therefore, we consider 13-substituted CBBR derivatives to be a novel class of anti-MRSA agents worthy of further investigation. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:877 / 886
页数:10
相关论文
共 29 条
[1]   Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen [J].
Bal, A. M. ;
David, M. Z. ;
Garau, J. ;
Gottlieb, T. ;
Mazzei, T. ;
Scaglione, F. ;
Tattevin, P. ;
Gould, I. M. .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2017, 10 :295-303
[2]  
Bi Chong-wen, 2013, Yaoxue Xuebao, V48, P1800
[3]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[4]   Antibacterial drug discovery in the resistance era [J].
Brown, Eric D. ;
Wright, Gerard D. .
NATURE, 2016, 529 (7586) :336-343
[5]   Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids [J].
Ernst, Christoph M. ;
Peschel, Andreas .
MOLECULAR MICROBIOLOGY, 2011, 80 (02) :290-299
[6]  
Fan T. Y., 2018, ACTA PHARM SIN, V8, P629
[7]   Discovery and Development of 8-Substituted Cycloberberine Derivatives as Novel Antibacterial Agents against MRSA [J].
Fan, Tianyun ;
Hu, Xinxin ;
Tang, Sheng ;
Liu, Xiaojia ;
Wang, Yanxiang ;
Deng, Hongbin ;
You, Xuefu ;
Jiang, Jiandong ;
Li, Yinghong ;
Song, Danqing .
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (05) :484-489
[8]   Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type distribution in methicillin-resistant Staphylococcus aureus bacteraemia [J].
Han, Jennifer H. ;
Edelstein, Paul H. ;
Lautenbach, Ebbing .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (10) :2346-2349
[9]   Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment [J].
Hassoun, Ali ;
Linden, Peter K. ;
Friedman, Bruce .
CRITICAL CARE, 2017, 21 :211
[10]   Antimicrobial activity of some 13-alkyl substituted protoberberinium salts [J].
Iwasa, K ;
Kamigauchi, M ;
Sugiura, M ;
Nanba, H .
PLANTA MEDICA, 1997, 63 (03) :196-198